Kairos Pharma, Ltd. (KAPA) Financials

KAPA Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 5.7 million 431000
Dec. 31, 2025 6.5 million 199000
Sept. 30, 2025 8.1 million 402000
June 30, 2025 6.7 million 676000

KAPA Free Cash Flow and Stock based compensation

No data available :(

KAPA Net Income

No data available :(

KAPA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 3.7 million - -
Dec. 31, 2025 4.5 million - -
Sept. 30, 2025 5.6 million - -
June 30, 2025 3.0 million - -

KAPA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 21.0 million
Dec. 31, 2025 18.4 million
Sept. 30, 2025 20.2 million
June 30, 2025 17.2 million

KAPA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 684000 1.0 million -
Dec. 31, 2025 838000 538000 837000 -
Sept. 30, 2025 838000 608000 787000 -
June 30, 2025 - 496000 920000 -

KAPA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 40000
Dec. 31, 2025 - -120000
Sept. 30, 2025 - 40000
June 30, 2025 - 40000

KAPA

Price: $0.46

52 week price:
0.42
2.11

Earnings Per Share: -0.30 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 10.2 million

Links: